

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	AOKI, et al.)	Examiner: (Parent App.: A. Gupta	a)
U.S. Serial No.:	PENDING)	Art Unit: (Parent App.: 1654)	PTO TO
Filed:	HEREWITH)		0405°
For:	METHOD FOR TREATING DYSTONIA WITH BOTULINUM TOXIN TYPE B	,))	Irvine, California	9/60/

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Applicant wishes to call to the attention of the Examiner the documents cited on the accompanying one-page Form PTO-1449. No concession is made that these documents are prior art, and applicant expressly reserves the right to antedate the documents as may be appropriate. Applicant requests that each of these documents be made of record in the above-identified application.

Many of these documents were cited in one or both of related applications Serial No. 08/627,118 filed April 3, 1996 and Serial No. 08/173,996 filed December 28, 1993. Therefore, only copies of those documents not cited in either of the prior related applications are enclosed.

Respectfully submitted,

Registration Number 33,433

Date: January 4, 2000

Allergan, Inc. 2525 Dupont Drive Irvine, CA 92612

Telephone: 714 246 4026 Fax: 714 246 4249

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this Information Disclosure Statement and any additional documents set forth as being enclosed herein are being deposited with the United States Postal Service on January 18, 2000, with sufficient postage as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, DC 20231.

MARY STICKLE

Name of person mailing paper

Mary Stickle
Signature of person mailing paper

Date: January <u>/8</u>, 2000